Mink therapeutics presents first-in-kind allo-inkts combination data in 2l gastric cancer at aacr io annual meeting

Addition of agent-797 with checkpoint inhibitors, bot/bal, and chemotherapy demonstrates robust immune activation, offering potential to overcome refractory gastric cancers addition of agent-797 with checkpoint inhibitors, bot/bal, and chemotherapy demonstrates robust immune activation, offering potential to overcome refractory gastric cancers
INKT Ratings Summary
INKT Quant Ranking